RNS Number : 6034U
N4 Pharma PLC
27 February 2026

27 February 2026

N4 Pharma plc

("N4 Pharma" or the "Company")

Notice of General Meeting and Proposed Change of Name to Thalia Therapeutics plc

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, announces its intention to change its name to Thalia Therapeutics plc, subject to approval by its shareholders at a general meeting of the Company (the "General Meeting") to be held on Tuesday, 17 March 2026 at 10.00 am at the offices of Arch Law Limited Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.

The proposed change of name reflects the Company's recently announced transition to a therapeutic biotechnology business focused on the development of innovative, high-value RNA-based therapeutics, alongside the continued advancement of its proprietary Nuvec® delivery platform. As outlined in the Company's announcement of 24 February 2026, the Board believes that the name Thalia Therapeutics plc more accurately represents the Company's expanded pipeline, new leadership and clear strategic direction as it advances internally generated RNA assets and pursues partnering opportunities to create long-term shareholder value.

The proposed change of name is subject to shareholder approval and the issue of a change of name certificate by Companies House. The Company's TIDM will be THAT, and its LEI, ISIN and SEDOL will remain unchanged. Existing share certificates will remain valid, and no new certificates will be issued.

Following registration of the change of name, the Company's website (containing the information required by AIM Rule 26) will be updated to reflect the new name, with further details announced at that time.

The proposed name change will be presented as a special resolution at the General Meeting. Details of the General meeting, including the time and venue, will be included in the Notice of General Meeting alongside a form of proxy, which has been dispatched to shareholders and made available on the Company's website at: https://investors.thaliatx.com/aim-rule-26

- Ends -

For more information please contact:

N4 Pharma plc
Dr Chris Britten, Chairman
Luke Cairns, Executive Director
Dr David H Solomon, CEO

Via Investor Hub
https://investors.thaliatx.com/link/rAOnxy

SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
Guy McDougall

Northstar Communications Limited Tel: +44 (0)20 7183 2463
Investor Relations
Sarah Hollins

N4 Pharma (to be renamed Thalia Therapeutics, subject to shareholder approval) is a pre-clinical biotech company focused on developing innovative RNA therapeutics and novel delivery systems to address high unmet needs in global healthcare.

RNA therapeutics is one of the most rapidly growing therapeutic sectors that is set to impact the treatment of a wide range of diseases. N4 Pharma is developing a wholly owned pipeline of novel RNA therapeutics for cardiovascular and other diseases, as well as developing Nuvec®, its proprietary gene delivery system, to further differentiate its therapeutic assets.

Nuvec® addresses multiple challenges associated with RNA therapeutics manufacturing and delivery, including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

For further information visit www.thaliatx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGSEMFWMEMSEEE